CA2865351C - Thiadiazolidinediones as gsk-3 inhibitors - Google Patents

Thiadiazolidinediones as gsk-3 inhibitors Download PDF

Info

Publication number
CA2865351C
CA2865351C CA2865351A CA2865351A CA2865351C CA 2865351 C CA2865351 C CA 2865351C CA 2865351 A CA2865351 A CA 2865351A CA 2865351 A CA2865351 A CA 2865351A CA 2865351 C CA2865351 C CA 2865351C
Authority
CA
Canada
Prior art keywords
compound
formula
solvate
disease
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2865351A
Other languages
English (en)
French (fr)
Other versions
CA2865351A1 (en
Inventor
Miguel Medina Padilla
Juan Manuel Dominguez Correa
Javier DE CRISTOBAL BLANCO
Ana Fuertes Huerta
Jorge Sanchez-Quesada
Javier Lopez Ogalla
Susana Herrero Santos
Maria Angeles Perez De La Cruz Moreno
Olga Martinez Montero
Beatriz Rodriguez Salguero
Francisco Palomo Nicolau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ASD Therapeutics Partners LLC
Original Assignee
ASD Therapeutics Partners LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ASD Therapeutics Partners LLC filed Critical ASD Therapeutics Partners LLC
Publication of CA2865351A1 publication Critical patent/CA2865351A1/en
Application granted granted Critical
Publication of CA2865351C publication Critical patent/CA2865351C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2865351A 2012-02-24 2013-02-22 Thiadiazolidinediones as gsk-3 inhibitors Active CA2865351C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382066.4 2012-02-24
EP12382066 2012-02-24
PCT/EP2013/053554 WO2013124413A1 (en) 2012-02-24 2013-02-22 Thiadiazolidinediones as gsk-3 inhibitors

Publications (2)

Publication Number Publication Date
CA2865351A1 CA2865351A1 (en) 2013-08-29
CA2865351C true CA2865351C (en) 2019-08-20

Family

ID=47747639

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2865351A Active CA2865351C (en) 2012-02-24 2013-02-22 Thiadiazolidinediones as gsk-3 inhibitors

Country Status (18)

Country Link
US (2) US9371299B2 (enExample)
EP (1) EP2838888B1 (enExample)
JP (2) JP6073377B2 (enExample)
AU (2) AU2013224041B2 (enExample)
CA (1) CA2865351C (enExample)
CY (1) CY1119231T1 (enExample)
DK (1) DK2838888T3 (enExample)
ES (1) ES2632428T3 (enExample)
HR (1) HRP20170964T1 (enExample)
HU (1) HUE035089T2 (enExample)
IN (1) IN2014DN07885A (enExample)
LT (1) LT2838888T (enExample)
NZ (1) NZ630615A (enExample)
PL (1) PL2838888T3 (enExample)
PT (1) PT2838888T (enExample)
SI (1) SI2838888T1 (enExample)
WO (1) WO2013124413A1 (enExample)
ZA (1) ZA201406225B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2838888B1 (en) 2012-02-24 2017-04-12 ASD Therapeutics Partners LLC Thiadiazolidinediones as gsk-3 inhibitors
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
MX388409B (es) * 2014-06-12 2025-03-19 Cedars Sinai Medical Center Composiciones y metodos para tratar canceres.
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
CN113168150B (zh) * 2018-10-16 2024-05-10 意大利技术联盟有限责任公司 具有被处理幅材的评估系统的卷绕机和方法
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
WO2022170437A1 (en) * 2021-02-11 2022-08-18 Venca Research, Inc. Compositions and methods for treating arrhythmogenic cardiomyopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
DE60129222T2 (de) * 2000-05-11 2008-03-06 Consejo Superior de Investigaciónes Científicas Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
EP1586318A1 (en) 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
KR100837785B1 (ko) * 2007-01-17 2008-06-13 한국화학연구원 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
EP2838888B1 (en) 2012-02-24 2017-04-12 ASD Therapeutics Partners LLC Thiadiazolidinediones as gsk-3 inhibitors

Also Published As

Publication number Publication date
ES2632428T3 (es) 2017-09-13
PT2838888T (pt) 2017-07-18
EP2838888B1 (en) 2017-04-12
CY1119231T1 (el) 2018-02-14
HUE035089T2 (hu) 2018-05-02
AU2017248556A1 (en) 2017-11-09
HK1207366A1 (en) 2016-01-29
EP2838888A1 (en) 2015-02-25
JP2017081974A (ja) 2017-05-18
CA2865351A1 (en) 2013-08-29
US20150038538A1 (en) 2015-02-05
US9371299B2 (en) 2016-06-21
US9469618B2 (en) 2016-10-18
US20160257660A1 (en) 2016-09-08
IN2014DN07885A (enExample) 2015-04-24
JP6518270B2 (ja) 2019-05-22
AU2013224041B2 (en) 2017-08-24
AU2017248556B2 (en) 2018-08-09
ZA201406225B (en) 2016-05-25
JP6073377B2 (ja) 2017-02-01
NZ630615A (en) 2015-09-25
HRP20170964T1 (hr) 2017-10-06
SI2838888T1 (sl) 2017-09-29
DK2838888T3 (en) 2017-07-17
WO2013124413A1 (en) 2013-08-29
PL2838888T3 (pl) 2017-12-29
AU2013224041A1 (en) 2014-09-25
JP2015508092A (ja) 2015-03-16
LT2838888T (lt) 2017-08-10

Similar Documents

Publication Publication Date Title
AU2017248556B2 (en) Thiadiazolidinediones as gsk-3 inhibitors
TWI352084B (en) Gsk-3 inhibitors
AU2007245625B2 (en) N- ( 2-thiazolyl) -amide derivatives as GSK-3 inhibitors
CA2616451C (en) Substituted benzyl derivatives as gsk-3 inhibitors
US20050054698A1 (en) 4-(4Methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3(gsk3)
JP2016525104A (ja) 非アポトーシス性の制御された細胞死の阻害剤としてのスピロキノキサリン誘導体
HK1207366B (en) Thiadiazolidinediones as gsk-3 inhibitors
WO2013149976A1 (en) Indole-pyrimidine derivatives and their therapeutic uses
EP2527322A1 (en) Carbamyl alkylphenyl disulfide derivatives and their therapeutic uses
EP2527323A1 (en) Urea carbonyl disulfide derivatives and their therapeutic uses
WO2013167635A1 (en) Therapeutic use of indole-dihydro-imidazole derivatives

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170814

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250214

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250214

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250214

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260216